Recent Products  
Since 2002 Planet Biotechnology has placed special emphasis on developing antibody therapeutics for emerging diseases, and biodefense countermeasures to known bio-warfare agents, including toxins, viruses and bacteria. With support from the National Institute of Allergy and Infectious Diseases (NIAID), we have developed an immunoadhesin for treatment and prevention of anthrax (PBI-220) and have tested it successfully in anthrax-infected monkeys as a therapeutic with an 80% survival rate when treatment is started after disease symptoms appear. We have conducted a pre-IND meeting with FDA and are seeking funding for the clinical testing of PBI-220.

Emerging Diseases
Middle East Respiratory Syndrome (MERS) is a recently emerged disease caused by the MERS coronavirus (MERS-CoV) endemic to the Arabian Peninsula. It has already appeared in seven Middle Eastern countries and has traveled to European countries and South Korea as well. MERS-CoV causes a pneumonia-like disease that has a fatality rate approaching 40%. We have created and produced in green plants an immunoadhesin (DPP4-Fc) that has improved binding to MERS-CoV and have shown that it prevents the virus from infecting human lung cells in culture. In June 2015 we were awarded a Phase II SBIR grant from NIAID to support development of this candidate immunoadhesin. We will be testing DPP4-Fc in animal models of MERS-CoV based on our encouraging in vitro data. 

Protein expression and purification services
We have considerable experience expressing human and chimeric IgA and IgG antibodies, immunoadhesins, nanobodies, and other proteins. Planet Biotechnology is a DARPA contractor (contract no. HR001113D-0004) for production of recombinant proteins in Nicotiana benthamiana.

Our proprietary codon optimization method enables unprecedentedly high expression levels of recombinant proteins in both transiently and stably transformed tobacco plants. We have achieved expression of IgG1 at levels up to 3 grams/kg of plant biomass after vacuum-assisted agroinfiltration. These high levels of expression, along with our proprietary purification methods, result in high product yield and purity.

We have research quantities of the following proteins available:

  • CMG2-Fc: immunoadhesin for treatment and prevention of anthrax, it consists of human extracellular CMG2 fused to human Fc
  • TEM8-Fc: human extracellular TEM8 domain fused to human Fc
  • BSG-Fc: human extracellular basigin domain (P. falciparum Rh5 receptor) fused to human Fc
  • AtCry1: Full-length, FAD-loaded Arabidopsis thaliana cryptochrome 1
    Customer testimonial: “Thank you for the fantastic [AtCry1] samples. They have been used to reveal very interesting reactivity in cryptochromes in regard to the amplification mechanism for boosting magnetic sensitivity” (Chemistry Department, Oxford University)

To find out more about our proteins and services, please email us at